PKRA83 (PKRA7) is a potent prokineticin 2 (PK2) antagonist that competitively inhibits the binding of PK2 to its receptors PKR1 and PKR2, with IC50 values of 5.0 nM and 8.2 nM, respectively; it exhibits anticancer, anti-arthritic, and anti-angiogenic activities and can penetrate the blood-brain barrier.